Glaucoma Overview
Glaucoma is a progressive disease characterized by the loss of retinal ganglion cells and changes in the neuroretinal rim tissue of the optic nerve, leading to narrowed visual fields and potential blindness.1
Prevalence
Glaucoma affects approximately 22 million eyes in the US. However, only about 13 million of these eyes have been diagnosed, and around 12 million are currently receiving treatment. Among those being treated, around 11.6 million are using eye drops. In contrast, only approximately 350,000 patients have undergone selective laser trabeculoplasty (SLT), and another 400,000 have received minimally invasive glaucoma surgery (MIGS). Additionally, about 1 in 5 cataract patients also have glaucoma, but only 350,000 are treated with MIGS (Figure 1).2,3
Figure 1. Prevalence of Glaucoma2,3
Etiology
The exact process by which glaucoma develops remains unclear. Intraocular pressure (IOP) depends on the balance between aqueous humor production by the ciliary body and its drainage through the trabecular meshwork and uveoscleral pathway, as shown below.1
Aqueous humor production/drainage1
Elevated IOP can put stress on the eye's posterior structures, especially the lamina cribrosa and surrounding tissues. The optic nerve fibers exit the eye at the lamina cribrosa, which is its weakest point and can be compressed or deformed under high IOP, leading to axonal damage and disrupted transmission. This process contributes to optic nerve injury characteristic of glaucoma and the gradual loss of retinal ganglion cells.1
Glaucomatous optic neuropathy can happen even with normal IOP, possibly due to low cerebrospinal fluid pressure around the optic nerve, creating a significant pressure difference. Other factors include impaired microcirculation, changed immune responses, excitotoxicity, and oxidative stress. Primary degenerative processes in nerve tissues can cause neurodegeneration of retinal neurons and central visual pathway cells, increasing their risk of injury.1
Acute closure glaucoma (ACG) patients often experience drainage obstructions, whereas patients with open-angle glaucoma (OAG) exhibit greater resistance to outflow.1
Risk Factors
There are several risk factors to consider, including age, gender, myopia, migraines, pigmentary dispersion syndrome, pseudo-exfoliation syndrome, diabetes, and smoking.1 Additional risk factors include race and family history, as illustrated in Figure 2.4
Figure 2. Glaucoma Risk Factors1,4
Diagnosis
Several factors must be considered when diagnosing glaucoma. A high IOP, above 22 mmHg, generally indicates glaucoma, but not everyone with elevated IOP will develop the condition. Additionally, visual field changes often occur, especially progressive midperipheral changes that gradually move inward, resulting in central or peripheral islands of vision.1
Detecting glaucoma early is challenging because the appearance of healthy individuals varies.1 During ophthalmic examination, the superior and inferior neuroretinal rims of the optic nerve are typically the first to be affected.5
Glaucoma can be categorized into mild, moderate, and severe as shown in Table 1.5
Table 1. Glaucoma Categories
The Traditional Glaucoma Treatment Algorithm
The treatment goal when managing glaucoma is to reduce IOP through medication, laser treatments, procedural pharmaceuticals, and other procedures to delay disease progression, maintain vision,1 and quality of life.1,7 The aim is a 20-50% reduction in IOP, but this is influenced by pre-treatment pressure levels associated with retinal damage, the severity of the damage, risk factors for progression, life expectancy, and treatment side effects.1
There are many first-line topical treatment options for patients. Ophthalmic drops include prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, and rho kinase inhibitors. Table 2 presents the mechanism of action and supplementary information for each drug.1,5
Table 2. Glaucoma First-line Topical Treatments1,5
The Need for Change
The question we should ask ourselves as clinicians is: Why are we treating patients with drops as primary therapy? With the growing population and increasing life expectancy of glaucoma patients, utilizing drops as primary therapy is already posing a number of challenges.
There are several shortcomings associated with topical drop therapy, and although it sometimes offers an effective short-term treatment option, adherence to treatment is crucial.1
Factors such as cost, side effects, and failure to reach the target IOP influence adherence,5 and adherence declines with multiple medications or increased dosing frequency.9 Lower adherence to anti-glaucoma therapy results in higher IOPs, increased fluctuations in IOP, and consequently worsening of glaucomatous visual field defects.10
Chronic use of topical medications can lead to a plateau effect, in which the medication's effectiveness is limited or even declines over time, necessitating increased dosing. About 40% to 75% of glaucoma patients use two or more medications, which leads to shorter-lasting benefits and higher health-related costs with each additional medication in a patient's glaucoma treatment plan.9
Higher rates of progression and blindness are associated with medications because they do not necessarily reduce IOP fluctuations, including both diurnal and nocturnal variability, which is why procedural intervention is often a better option.9 Based on this understanding, topical drops are best used as a bridge and supplementary therapy.6
The interventional glaucoma (IG) approach shifts from a reactive, medication-focused model to a more proactive, procedure-based strategy. Early, or first-line, proactive procedural intervention may shift the disease trajectory rather than just delaying further procedures and surgery. That is, earlier intervention can help slow disease progression, potentially delaying or preventing visual disability as shown below.9
Change in trajectory with earlier intervention9
IG approaches do not aim to completely eliminate medications, which can still be a crucial part of glaucoma treatment in many regions. Instead, they challenge the routine prescription of medications as the primary and often only response in managing glaucoma. Similarly, they do not exclude filtering surgery for suitable patients but advocate earlier interventions to potentially avoid it altogether.12 Topical medication can be used as a bridge or supplemental therapy.6
The IG protocol involves customized pathways tailored to different stages of glaucoma, from OHT to advanced disease. Treatment decisions are based on patient-centered factors, including experiences before, during, and after the procedure, as well as future treatment options.6
The urgency of lowering IOP also guides the treatment plan. Options are categorized by stage and include procedural pharmaceuticals, laser treatments, tissue-sparing and non-tissue-sparing MIGS, filtering surgery, and topical medications. This framework helps providers apply IG principles and enhance patient care.6
Expanding Portfolio of Treatment Options
Procedural Pharmaceuticals
Procedural pharmaceuticals, including travoprost and bimatroprost implants, deliver the drug continuously, lowering IOP, total dosage, and systemic exposure, thereby decreasing the risk of side effects.13 It reduces the need to remember to take medication and addresses compliance challenges.13
iDose® TR is a sustained-release intraocular implant with 3 primary components (iDose TR prescribing information)16:
- Scleral anchor for insertion and secure attachment to the inner scleral wall via the trabecular meshwork
- Titanium body serving as a drug reservoir
- Membrane designed to release travoprost gradually over a targeted duration, designed to last up to 3 years.
The implant is designed to remain fixed and stable, positioned parallel to the iris and away from the corneal endothelium (iDose TR prescribing information).16
Animation: iDose TR procedure
A phase 3 study assessed the efficacy and safety of iDose TR in patients with OHT and OAG. It involved two Phase 3, parallel-group, double-masked, randomized, prospective, sham-controlled trials comparing iDose TR to topical timolol (0.5%) BID. At 3 months, iDose TR met the primary efficacy endpoint of non-inferiority to topical timolol. At 12 months, 81% of iDose TR participants were completely free of IOP-lowering topical medications, with 23% initially on two or more medications before the trial.14
In a 36-month follow-up analysis of phase 3 trials, data showed that 70% of iDose TR subjects remained controlled on the same or fewer IOP-lowering medications at 36 months after a single dose, compared with 58% of timolol subjects. It also showed continued excellent tolerability and safety over the 36-month duration.17
Most common ocular adverse events (OAEs) included increased IOP, eye pain, iritis, ocular hyperemia, dry eye, reduced visual acuity, and visual field defects. Most OAEs were mild or moderate and resolved.16
Lasers
Laser procedures effectively lower the IOP and minimize the long-term costs associated with the use of multiple pressure-lowering medications.5 It is considered to be minimally invasive and has a reasonable safety profile.5
For refractory OAG, particularly in patients not responding to pharmacological therapy, laser trabeculoplasty should be considered. Argon laser trabeculoplasty (ALT) employs a blue-green continuous-wave laser (488 and 514 nm) to disrupt the TM. Selective laser trabeculoplasty (SLT) uses low-energy, brief-duration, large-spot pulses from a green, frequency-doubled laser to target melanin-containing cells while sparing the TM tissue. SLT has become popular due to its favorable safety profile, comparable IOP-lowering efficacy, and the ability for repeated treatments. Other types of laser trabeculoplasty include titanium-sapphire laser trabeculoplasty and pattern scanning trabeculoplasty.5
Animation: SLT
Laser peripheral iridotomy (LPI) and laser peripheral iridoplasty are most effective for patients with ACG. There are some differences between the two procedures. Laser peripheral iridotomy involves creating a hole in the peripheral iris and is often performed to eliminate pupillary block. In contrast, laser peripheral iridoplasty utilizes low-power laser burns to reduce appositional angle closure by shrinking the peripheral iris when laser iridotomy is ineffective.5
Combining both treatments is safe and effective for lowering the IOP in eyes with acute primary ACG that do not respond to medication. For eyes unresponsive to other treatments, cyclodestructive procedures that damage the ciliary body can lower IOP by decreasing aqueous humor production. These procedures are also useful for secondary glaucoma types, such as uveitic, traumatic, or neovascular glaucoma, but can be challenging to control and carry risks.5
In the following sections, we will discuss the different minimally invasive glaucoma surgery (MIGS) options.
MIGS: Trabecular Outflow Pathway
Trabecular Bypass Implant
The three anatomically designed trabecular bypass stents (iStent infinite®) are designed to optimize outflow while causing minimal disruption to natural anatomy by occupying only 3% of Schlemm’s canal, leaving 97% untouched. This, together with a patented multidirectional stent design, helps bypass resistance and restores natural outflow.18
In the prospective, multicenter, 12-month pivotal trial, patients with open-angle glaucoma who had failed prior surgical and medical therapy underwent standalone iStent infinite® implantation.19
- 91.7% of patients in the failed prior surgery group reduced or maintained medication burden at 12 months19
- 80.0% of patients in the failed prior surgery group had >20% IOP reduction19
- 47.3% of patients in the failed prior surgery group had >30% IOP reduction19
Additionally, exceptional intraoperative and postoperative safety was shown among patients with two or more failed filtering surgeries. Only 4.9% of eyes needed secondary surgical intervention after iStent Infinite implantation over 12 months, despite multiple previous surgical failures. Additionally, there was no Hypotony, explant, cyclodialysis clefts, or device-related interventions.19
Animation: iStent Infinite® procedure
The iStent inject® W is indicated for use in conjunction with cataract surgery to lower IOP in adult patients with mild to moderate primary open-angle glaucoma.20 It creates two bypass pathways through the trabecular meshwork, which is the main resistance to aqueous outflow, allowing flow in multiple directions through Schlemm’s canal. It is among the smallest medical devices implanted in the human body.20 Glaukos trabecular micro-bypass stents are positioned two to three clock hours apart, designed to access multiple collector channels and flow arches spanning up to five to six clock hours. They may also help restore flow in dormant outflow channels.21
The iStent inject® W with Infinite Injector Technology (Figure 3) shares the same indication and mechanism of action as the iStent inject® W. The main difference is that it allows unlimited stent delivery attempts using an advanced injector.22
Figure 3. iStent inject® W with Infinite Injector Technology
Ab-interno canaloplasty
Ab-interno canaloplasty targets the trabecular outflow pathway. It is not suitable for severe glaucoma but has comparable safety and efficacy to ab-externo canaloplasty5
Ab-interno trabeculotomy
Ab-interno trabeculotomy also targets the trabecular outflow pathway. This procedure and goniotomy procedures create direct communication between the anterior chamber, Schlemm's canal, and distal collector channels by disrupting or partially removing the TM5
Excisional goniotomy
Excisional goniotomy is performed using the iAccess Precision Blade® (Glaukos). Trabeculectomy and goniotomy can be performed concurrently. Due to the nature of the procedure, it creates a clean excision of the TM, which limits fibrosis and closure.5
MIGS: Subconjunctival Space
These surgeries redirect aqueous humor flow directly into the subconjunctival space. One of the issues with surgeries in this space is that it may lead to subconjunctival fibrosis. However, in surgeries such as a trabeculectomy, it may be prevented with intraoperative application of mitomycin-C.5
MIBS: Minimally Invasive Bleb Surgery
IOP decreases through the implantation of a device that creates a new pathway for eye fluid drainage, known as subconjunctival outflow. Bleb fibrosis is the most common cause of surgical failure, and the use of mitomycin-C may reduce its occurrence. MIBS may be safer than trabeculectomy and cause fewer follow-ups, but current evidence remains uncertain.23
MIGS: Suprachoroidal Space
These surgeries enhance uveoscleral outflow. The uveoscleral pathway is not limited by the pressure “floor” caused by episcleral venous pressure; therefore, diverting the aqueous humor into the suprachoroidal space could offer a greater IOP-lowering effect. However, long-term effectiveness may be restricted by fibroblast migration and growth, and studies on efficacy are needed.5
Traditional Surgical Treatment
Trabeculectomy involves creating a partial-thickness scleral flap and removing a segment of the trabecular meshwork to establish an alternative drainage pathway into the subconjunctival space. It has been considered the “Gold standard” glaucoma surgery for decades because it effectively controls intraocular pressure (IOP), especially aiming for the low teens to slow glaucoma progression.5
Glaucoma drainage devices (tube shunts) create a permanent sclerostomy to drain aqueous humor into the subconjunctival space. They serve as an alternative to trabeculectomy by reducing conjunctival scarring by diverting aqueous drainage to the equatorial region of the eye, away from the limbus, leading to the formation of a permanent bleb (plate tube).5
The main issue with traditional surgeries is their high complication rates. Potential complications from these procedures can include the formation of scar tissue, endophthalmitis, and conjunctival hemorrhage. Additionally, the effectiveness of these surgeries in lowering intraocular pressure (IOP) often decreases over time, leading to higher reoperation rates after 5 years. These unsuccessful surgeries and complications may require further postoperative intervention.5
What to do, when and why
The traditional reactive treatment of drops, laser, and filtering procedures has drawbacks that limit its suitability for a chronic, progressive, irreversible, and vision-threatening disease like glaucoma.9
Below is an overview of the treatment protocols for OHT, mild, moderate, and severe glaucoma.
Animation: Treatment Protocols for Ocular Hypertension, Mild Glaucoma, Moderate Glaucoma, and Severe Glaucoma.
The IG consensus protocol assumes that the patient is previously undiagnosed and untreated, with no other significant comorbidities.6
The issue with monotherapy is that it uses single-mechanism, single-modality treatments, which often fail to achieve adequate IOP control, necessitating multi-mechanism and multi-modal approaches.11
The rationale to utilize procedures as primary therapy is that early IOP reduction and control of IOP fluctuations can prevent disease progression and thus a second surgery, improve patient satisfaction, and be cost-effective over time, thereby enhancing long-term outcomes.11
The Multimodal/multi-mechanism approach utilizes multiple methods to lower IOP and combines treatments—medications, laser therapy, and procedure—early in the process, rather than sequentially, as in traditional practice, to maximize the available options.11
Multi-mechanism therapy targets various aspects of IOP regulation, including trabecular outflow, uveoscleral outflow, and aqueous suppression, utilizing medications, laser therapy, and surgical interventions.11 With a multidrug regimen, it is beneficial to choose drugs with complementary mechanisms of action to target multiple components of the IOP regulation pathway. Multiple procedures can be combined to enhance therapeutic effectiveness by targeting different mechanisms of IOP reduction, such as combining canaloplasty with trabeculotomy to lower both trabecular and post-trabecular outflow resistance. Together, a multi-mechanism approach can effectively target some or all of the factors that influence IOP, facilitating comprehensive IOP management.11
Multi-modal therapy combines different treatment modalities (e.g., medications and MIGS) concurrently rather than sequentially, providing significant and lasting IOP reduction while reducing medication burden.11
Micheletti et al. pointed out that the Collaborative Initial Glaucoma Treatment Study (CIGTS) showed that surgery effectively prevented visual field loss, but medical therapy was equally effective in mild to moderate glaucoma and less so in advanced cases, due to similar target IOP levels. However, the high medication burden and nonadherence suggest that such regimens may be less effective outside of clinical trials.11
The Argument for Standalone MIGS versus MIGS + Cataract Surgery
In the past, MIGS was combined with cataract surgery. However, it was not a lack of clinical efficacy but rather practical and regulatory issues that initially limited many MIGS procedures to cataract surgery. The issue with this approach is that linking glaucoma treatment to cataract surgery may unnecessarily limit patients' options to a narrow window.9
Cataract surgery leads to a modest reduction in intraocular pressure (IOP), with a decrease of less than 2 mm Hg, corresponding to a 16.5% reduction after 3 years. Evidence indicates that the reduction in IOP is more significant one year after cataract surgery, but over time, IOP tends to return to baseline levels.9
IG is a proactive approach as it advocates for earlier procedural intervention regardless of lens status. This approach seeks to lower and maintain IOP, delay or avoid high-risk surgery, and reduce the burden on patients by lowering their medication load.9
Standalone MIGS complements an interventional, proactive approach. It offers a crucial option for patients who need better solutions than ineffective drops and serves as an alternative to riskier filtering surgeries. More than 50 scientific studies have confirmed the safety and effectiveness of trabecular micro-bypass when used alone. These devices demonstrate comparable efficacy among themselves, and, specifically for iStent and iStent inject, they share similar overall and corneal endothelial safety profiles with cataract surgery alone.
With IG, individual patients achieve the lowest IOP possible without excessive risk and have the best chance of preventing disease progression from the start.11
IG Benefits the Patient, Practice, and HCP
IG is a patient-centric framework.6 There is some diminished quality of life (QOL) associated with eye drop usage,24 and early procedural intervention seeks to alleviate the negative quality of life impact associated with eye drop usage.6 Drop usage can lead to depression, anxiety, lower self-image, and reduced confidence in healthcare. Patients may feel they lack control over their disease, especially when it progresses.24
Interventional glaucoma prioritizing procedures over drops results in more consistent IOP control, better patient compliance, a lower medication burden, and a faster recovery time (Katz, 2024).12 It also avoids unwanted side effects of topical medications, such as ocular surface disease, hyperemia, hyperpigmentation of eyelids and iris, and systemic reactions that can result in death (Gallardo, 2024).24
Medications tend to reach a plateau effect and may lose efficacy over time.24 Early procedural intervention aims to preserve vision more effectively, consistently, reliably, and comfortably.6 74% of patients with glaucoma who had been using drops for at least 6 months had ocular surface disease (OSD).25
Medications can also place a burden on caregivers and relatives, as ongoing treatment might be more demanding than the disease itself. Patients may experience difficulties with reading, driving, and mobility. There can also be financial and psychological implications for their caregivers and family members.24
For healthcare professionals and their practices, IG provides a practical framework or protocol that serves as a starting point.6 It leads to fewer intraoperative complications, easier follow-up care, and better tissue preservation in case of future surgery.12
IG incorporates patient education into the clinical flow, with staff members educating patients during pre-testing, while they wait to be seen, and after the exam. Taking the time to provide targeted education on disease processes and treatment options can reduce anxiety about the disease and enhance patient knowledge.
Collaborative Care
The Importance of Education in Collaborative Care
The established consensus treatment protocol shapes patient care by guiding the next steps in education. It must be led by doctors to avoid confusion, since patients tend to trust their doctors to recommend what is best. Consequently, it is crucial to educate referring doctors so they can appropriately inform their patients. Many glaucoma specialists mainly receive referrals from optometrists, and since glaucoma is a progressive and hard-to-control disease, referrals are common. Patients visiting corporate and private optometry practices often make good candidates for SLT or procedural pharmaceuticals. Early procedural intervention aims to prevent the development of refractory glaucoma, which is difficult to treat.
Building a Referral Network
Collaborative care is essential when implementing IG in your practice. Building a referral network with local optometrists and ophthalmologists is crucial, though it can seem challenging at first. Some optometrists are only comfortable with sending referrals to doctors with whom they have a relationship and feel like there is a willingness to work with them. An effective strategy to build this relationship is hosting educational events. Make it easy for optometrists and other referring doctors to contact you, whether through follow-up conversations about patients or by offering simple ways to text you when needed. If you have optometrists on your staff, they can also help facilitate referrals.
You can also create practice-related marketing tools, such as handouts of the consensus protocol and basic information about your services. To further increase awareness, reach out to companies with a list of optometrists to educate them about your treatment options.
Establishing Referral Protocols
Provide referral forms to referring doctors, including details like previous procedures, the highest recorded (max) IOP (Tmax), and current ophthalmic and systemic medications. This helps minimize redundant tests and allows providers to conduct further tests if needed. While referring doctors don't need to know every option the practice offers, they should be aware that options exist. Emphasize that early procedural intervention is crucial for preserving vision and maintaining a high quality of life. Early referrals educate patients about available treatments, helping them understand the procedures and make informed decisions about proceeding.
Best Practices
There are a few best practices for collaborative care based on our experience. For patients with mild to moderate glaucoma, perform SLT or procedural pharmaceuticals as the intervention and refer back to the optometrist for management. For patients with severe glaucoma, both the glaucoma specialist and optometrist should monitor for progression. This increases the number of pressure checks/contact with the patient, so there is a greater chance that progression is caught before it becomes an issue.
Key Takeaways
The main point is to invest in yourself and your patient. Take the time to refine your diagnostic skills, such as practicing good gonioscopy, understanding the evidence, and understanding the rationale behind various protocols, to enhance your communication with patients. It’s also essential to develop the ability to perform gonioscopy and procedures such as procedural pharmaceuticals and SLT, accurately.
Talking about lasers and procedures can be intimidating, but if you genuinely believe in what you're doing, your patients will respect that. They will see that you're doing it for their benefit, not for any other reason. When you present your case from the patient’s perspective and focus on their best interests, things tend to go very smoothly. The responsibility falls on us. We are physicians who have taken an oath to care for patients and help them lead the best lives possible. We do this through their eyes, by managing their disease. If we truly believe in this mission, we should assume the burden of care instead of passing it on to patients, which can be stressful, frightening, and fraught with side effects and risks.
As doctors, we're prepared to handle these challenges, and patients shouldn’t have to. IG represents a shift in the treatment of glaucoma, helping to preserve vision for patients.
PM-US-3431
The Faculty were compensated by Glaukos for their time.